XXXX XXXX XXXX XXXX（XXXX）是第一项评估IMRT用于头颈部肿瘤多机构可行性的临床试验。二年局部区域失败和急性口干症状减轻是主要终点，此前已有报道。此报告提供了经过长期随访的次要终点。符合资格的患者为T1-2、N0-1咽喉癌患者。次要终点包括疾病控制和总生存率。局部区域失败率由累计发生率法估计，疾病无瘤生存率和总生存率由Kaplan-Meier法估计。晚期毒性经XXXX/EORTC标准分级，并用描述性统计报告。分析了69名受试者中的67名。其中50名患者（75％）为T2病情，38名（57％）为淋巴结阴性（N0）。中位随访时间为11.9年。估计的10年局部区域失败率、无病生存率和总生存率分别为15％（95％CI为8-25）、50％（95％CI为38-62）和67％（95％CI为55-78）。最高的晚期毒性报告为：5级：0％，4级：9％，3级：13％和2级：63％。3-4级晚期毒性涉及黏膜（7％）、骨头（4％）、食管（4％）、唾液腺（4％）、疼痛（3％）、体重减轻（1％）和出血（1％）。2-3级唾液腺毒性报告比例为70％，但随着时间而改善。41名（74.5％）和17名（42.5％）存活患者在 5年和10年以上进行了毒性评估。基于早期开展的头颈部IMRT治疗的前瞻性数据集，此XXXX/XXXX XXXX的报告提供了早期技术的基准长期结果。在10年内，三分之二的患者仍然健在，且晚期3-4级毒性水平可接受。 版权所有©2023。Elsevier Inc. 发布。

XXXX XXXX XXXX XXXX (XXXX) XXXX was the first clinical trial evaluating multi-institution feasibility of IMRT for head and neck cancer. The primary endpoints of 2-year local-regional failure and reduction in acute xerostomia were reported previously. This report provides secondary endpoints with long-term follow-up.Eligibility included patients diagnosed with T1-2, N0-1 oropharyngeal cancer. Secondary endpoints included disease control and overall survival. Local-regional failure rates were estimated by the cumulative incidence method, and disease-free and overall survival rates were estimated by the Kaplan-Meier method. Late toxicities were graded by XXXX/EORTC criteria and are reported with descriptive statistics.Sixty-seven of 69 enrolled patients were analyzed. Fifty patients (75%) had T2 disease and 38 (57%) were node negative (N0). Median follow-up was 11.9 years. Estimated 10-year local-regional failure, disease-free survival and overall survival rates were 15% (95%CI 8-25), 50% (95%CI 38-62) and 67% (95%CI 55-78), respectively. Highest reported late toxicities were: grade 5: 0%, grade 4: 9%, grade 3: 13%, and grade 2: 63%. Grade 3-4 late toxicities involved mucous membranes (7%), bone (4%), esophagus (4%), salivary gland (4%), pain (3%), weight loss (1%), and hemorrhage (1%). Grade 2-3 salivary gland toxicity was reported in 70% but improved over time. Forty-one (74.5%) and 17 (42.5%) of surviving patients had a toxicity assessment at > 5 years and >10 years, respectively.This report of XXXX/XXXX XXXX, based on an early, prospectively collected dataset of head and neck IMRT treatments, provides benchmark long-term outcomes of this early version of the technology. At 10 years, 2/3 of patients were alive, with an acceptable level of grade 3-4 late toxicities.Copyright © 2023. Published by Elsevier Inc.